0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Inhibitors of Cholesterol Synthesis and Cataracts-Reply

Donald B. Hunninghake, MD; Valery T. Miller, MD; Robert H. Palmer, MD; Gustav Schonfeld, MD; Evan A. Stein, MD, PhD; Jonathan A. Tobert, MB, PhD
JAMA. 1987;257(12):1602. doi:10.1001/jama.1987.03390120064021.
Text Size: A A A
Published online

In Reply.—  Dr Cenedella is correct in pointing out the potential for inhibitors of cholesterol synthesis to induce cataracts, particularly in young individuals. Pediatric use of lovastatin has been limited to patients with serious genetic disorders, mainly children with homozygous familial hypercholesterolemia. One of us (J. A.T.) has analyzed results of all the ophthalmologic examinations in patients taking lovastatin. Slit-lamp examination of the lens was performed at the baseline examination and during treatment in over 500 patients. The mean age of the patients studied was 50 years; 60% of them had heterozygous familial hypercholesterolemia and 50% had ischemic heart disease. The prevalence of lens opacities in these patients was 27% at the baseline examination and 31% at the last available examination during treatment with lovastatin. Interpretation of these data is complicated by the subjective nature of slit-lamp examination, uncertainty regarding the natural incidence of lens opacities in patients with severe

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();